A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
BACKGROUND: Despite the availability of efficacious drugs, the success of treating hypertension is limited by patients' inconsistent drug intake. Immunization against angiotensin II may offer a valuable alternative to conventional drugs for the treatment of hypertension, because vaccines induce relatively long-lasting effects and do not require daily dosing. Here we describe the preclinical development and the phase I clinical trial testing of a virus-like particle (VLP)-based antihypertensi...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date: